Press Release: Io Biotech Announces Publication Of Five-Year Clinical Outcomes Of Phase 1/2 Trial In Nature Communications

Reuters

Risk Warnings and Disclaimers

You understand and acknowledge that there is a high degree of risk involved in trading. Following any strategies or investment methods may lead to potential losses. The content on the site is provided by our contributors and analysts for information purposes only. You are solely responsible for determining whether any trading assets, securities, strategy, or any other product is suitable for investing based on your own investment objectives and financial situation.

Add to Favorites

Io Biotech Announces Publication Of Five-Year Clinical Outcomes Of Phase 1/2 Trial In Nature Communications

Reuters

IO Biotech

-2.27%

Risk Warnings and Disclaimers

Add to Favorites

IOBT: IO102-IO103 demonstrates strong efficacy and safety in melanoma, with pivotal new trials and EU plans ahead

Quartr

IO Biotech

-2.27%

Recent data show IO102-IO103 plus pembrolizumab delivers meaningful PFS and OS benefits in metastatic melanoma, with a strong safety profile and pan-tumor potential. Regulatory strategy now focuses on a new global trial with Opdualag and EU engagement, while early pipeline assets advance toward the clinic.

Based on IO Biotech, Inc. [IOBT] Piper Sandler 37th Annual Healthcare Conference Audio Transcript — Dec. 3 2025

Disclaimer

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Risk Warnings and Disclaimers

Add to Favorites

IOBT: IO102-IO103 shows strong clinical promise in melanoma, with pivotal new trials and EU filings ahead

Quartr

IO Biotech

-2.27%

Phase III data for IO102-IO103 in melanoma showed meaningful PFS and OS trends with strong safety, though FDA BLA submission was not recommended due to statistical significance. New global trials and EU regulatory discussions are underway, with pipeline expansion and a solid cash runway into 2026.

Based on IO Biotech, Inc. [IOBT] Piper Sandler 37th Annual Healthcare Conference Audio Transcript — Dec. 3 2025

Disclaimer

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Risk Warnings and Disclaimers

Add to Favorites

IOBT: Strong PFS benefit in PD-L1 negative melanoma drives plans for larger global phase III trial

Quartr

IO Biotech

-2.27%

The T-win platform demonstrated strong PFS benefits in melanoma, especially in PD-L1 negative patients, though the phase III narrowly missed statistical significance. Plans are underway for a larger, global phase III trial with updated comparators, while pipeline expansion and new trials in other cancers are progressing. Funding strategies include partnerships, especially in Europe.

Based on IO Biotech, Inc. [IOBT] Evercore ISI 8th Annual HealthCONx Conference Audio Transcript — Dec. 2 2025

Disclaimer

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Risk Warnings and Disclaimers

Add to Favorites

IOBT: Strong PFS benefit in PD-L1 negative melanoma drives plans for a larger phase three trial

Quartr

IO Biotech

-2.27%

The conference highlighted strong PFS results for a cancer vaccine platform, especially in PD-L1 negative melanoma patients, and outlined plans for a larger phase three trial with updated comparators. Financial strategy includes seeking EU partnerships and non-dilutive funding.

Based on IO Biotech, Inc. [IOBT] Evercore ISI 8th Annual HealthCONx Conference Audio Transcript — Dec. 2 2025

Disclaimer

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Risk Warnings and Disclaimers

Add to Favorites

Io Biotech Announces Participation In Upcoming December Investor Conferences

Reuters

IO Biotech

-2.27%

Risk Warnings and Disclaimers

Add to Favorites

Risk Disclosure

The risk of loss in trading financial instruments such as stocks, FX, commodities, futures, bonds, ETFs and crypto can be substantial. You may sustain a total loss of the funds that you deposit with your broker. Therefore, you should carefully consider whether such trading is suitable for you in light of your circumstances and financial resources.

No decision to invest should be made without thoroughly conducting due diligence by yourself or consulting with your financial advisors. Our web content might not suit you since we don't know your financial conditions and investment needs. Our financial information might have latency or contain inaccuracy, so you should be fully responsible for any of your trading and investment decisions. The company will not be responsible for your capital loss.

Without getting permission from the website, you are not allowed to copy the website's graphics, texts, or trademarks. Intellectual property rights in the content or data incorporated into this website belong to its providers and exchange merchants.

Recent Searches

Top Searches

Markets

News

Analysis

User

24/7

Economic Calendar

Education

Data

Press Release: Io Biotech Announces Publication Of Five-Year Clinical Outcomes Of Phase 1/2 Trial In Nature Communications

Io Biotech Announces Publication Of Five-Year Clinical Outcomes Of Phase 1/2 Trial In Nature Communications

IOBT: IO102-IO103 demonstrates strong efficacy and safety in melanoma, with pivotal new trials and EU plans ahead

IOBT: IO102-IO103 shows strong clinical promise in melanoma, with pivotal new trials and EU filings ahead

IOBT: Strong PFS benefit in PD-L1 negative melanoma drives plans for larger global phase III trial

IOBT: Strong PFS benefit in PD-L1 negative melanoma drives plans for a larger phase three trial

Io Biotech Announces Participation In Upcoming December Investor Conferences

Risk Disclosure